Prescribed Walking for Glycemic Control and Symptom Management in Patients Without Diabetes Undergoing Chemotherapy.

Nurs Res

Marilyn J. Hammer, PhD, DC, RN, FAAN, is the Director, Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, and Member of the Faculty, Medical Oncology, Harvard Medical School, Boston, Massachusetts. Patricia Eckardt, PhD, RN, FAAN, is Professor, Barbara H. Hagan School of Nursing and Health Sciences, Molloy College, Rockville Center, New York. Frances Cartwright, PhD, RN, AOCN, FAAN, is the Chief Nursing Officer and Senior Vice President, Department of Nursing, The Mount Sinai Hospital, and Associate Professor, Icahn School of Medicine at Mount Sinai, New York, New York. Christine Miaskowski, PhD, RN, FAAN, is Professor and Vice Chair for Research, Sharon Lamb Endowed Chair in Symptom Management Research, and American Cancer Society Clinical Research Professor, University of California, San Francisco.

Published: February 2021

Background: Hyperglycemia may potentiate symptom experiences. Exercise is a nonpharmacological intervention that can potentially improve glycemic control and mitigate symptom experiences in patients undergoing chemotherapy for cancer.

Objectives: The primary objective was to assess the feasibility of patients engaging in a walking exercise study for 6 months. We also evaluated the effects of a prescribed walking program on glycemic control and for changes over time in the severity of pain, fatigue, depression, and sleep disturbance in patients undergoing chemotherapy for breast, lung, gynecologic, or gastrointestinal cancer.

Methods: A randomized pilot intervention study was conducted to evaluate differences within and between a prescribed walking program intervention group and a control group. All patients were followed for 6 months, had glycosylated hemoglobin A1c measured at enrollment and 6 months, and completed symptom questionnaires at enrollment, 3 months, and 6 months. Data were analyzed using descriptive statistics and analysis of covariance.

Results: Most of the patients who enrolled completed the 6-month study. The few who withdrew expressed feeling overwhelmed. The sample was predominately non-Hispanic White female patients with breast cancer with a normal-to-slightly-overweight body mass index. The intervention group had a slight decrease in glycosylated hemoglobin A1c at 6 months. In addition, at 6 months, compared to the control group, the intervention group had significantly less sleep disturbance and depression. No other within- or between-group differences were found.

Discussion: It is feasible for patients undergoing chemotherapy to participate in a prescribed walking program. Exercise, such as walking, may decrease hyperglycemia and symptom severity. Additional research with larger samples is warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1097/NNR.0000000000000468DOI Listing

Publication Analysis

Top Keywords

prescribed walking
16
undergoing chemotherapy
16
glycemic control
12
patients undergoing
12
walking program
12
intervention group
12
patients
8
symptom experiences
8
sleep disturbance
8
control group
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!